LAMIVUDINE
- Product NDC
- 69097-167
- 11-digit product format
- 690970167
- Labeler code
- 69097
- Product ID
- 69097-167_65d03051-a84c-49d7-928b-515cb1769bec
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- LAMIVUDINE
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Cipla USA Inc.
- Application
- ANDA077221
- Marketing category
- ANDA
- Marketing start
- 2017-03-03
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 69097-167 | LAMIVUDINE TABLET [CIPLA USA INC.] | 9 | Legacy NDC | 20190610_36b83d9a-962f-4821-bf44-0bace705b620.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 69097-167-02 | 69097016702 | 30 TABLET in 1 BOTTLE (69097-167-02) | 30 tablet | 2017-03-03 | 0000-00-00 | No | No | Current |